Zenas BioPharma, Inc./$ZBIO
13:30
09:10
04:45
00:25
20:00
1D1W1MYTD1Y5YMAX
About Zenas BioPharma, Inc.
Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them.
Ticker
$ZBIO
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
130
Website
ZBIO Metrics
BasicAdvanced
$657M
-
-$7.00
-
-
Price and volume
Market cap
$657M
52-week high
$16.73
52-week low
$6.11
Average daily volume
170K
Financial strength
Current ratio
6.468
Quick ratio
6.393
Long term debt to equity
0.111
Total debt to equity
0.431
Profitability
EBITDA (TTM)
-173.513
Gross margin (TTM)
-901.59%
Net profit margin (TTM)
-1,085.07%
Operating margin (TTM)
-1,157.60%
Effective tax rate (TTM)
-0.14%
Revenue per employee (TTM)
$120,000
Management effectiveness
Return on assets (TTM)
-56.70%
Return on equity (TTM)
-115.47%
Valuation
Price to revenue (TTM)
24.362
Price to book
2.31
Price to tangible book (TTM)
2.31
Price to free cash flow (TTM)
-2.653
Free cash flow yield (TTM)
-37.70%
Free cash flow per share (TTM)
-5.922
Growth
Revenue change (TTM)
-70.00%
Earnings per share change (TTM)
-76.46%
Bulls say / Bears say
Zenas BioPharma has completed targeted enrollment for its Phase 3 INDIGO trial, the largest clinical trial conducted in patients with IgG4-Related Disease, with topline results expected by the end of 2025. (zenasbio.com)
The company initiated the Phase 2 MoonStone trial for Relapsing Multiple Sclerosis and the Phase 2 SunStone trial for Systemic Lupus Erythematosus, with results anticipated in 2025 and 2026, respectively. (zenasbio.com)
Zenas BioPharma raised $258.7 million in gross proceeds from its initial public offering in September 2024, providing substantial capital to fund its growth strategy and clinical development programs. (zenasbio.com)
A class action lawsuit has been filed against Zenas BioPharma, alleging that the company overstated its financial position in its IPO registration materials, leading to a significant decline in stock price. (globenewswire.com)
The company's stock price has fallen substantially below its IPO price, closing at $8.72 on April 15, 2025, representing a 48.7% decline from the IPO price. (globenewswire.com)
Zenas BioPharma reported a net loss of $38.6 million for the quarter ended September 30, 2024, compared to net income of $35.6 million for the same period in 2023, indicating financial challenges. (zenasbio.com)
Data summarised monthly by Lightyear AI. Last updated on 13 Jul 2025.
ZBIO News
AllArticlesVideos
Investors Urged to Contact Levi & Korsinsky for Information Before June 16, 2025 - Zenas BioPharma, Inc. (ZBIO)
Accesswire·2 months ago
June 16, 2025 Deadline: Join Class Action Lawsuit Against Zenas BioPharma, Inc. (ZBIO) - Contact Levi & Korsinsky
Accesswire·2 months ago
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Zenas BioPharma, Inc. of Class Action Lawsuit and Upcoming Deadlines - ZBIO
Accesswire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Zenas BioPharma, Inc. stock?
Zenas BioPharma, Inc. (ZBIO) has a market cap of $657M as of August 01, 2025.
What is the P/E ratio for Zenas BioPharma, Inc. stock?
The price to earnings (P/E) ratio for Zenas BioPharma, Inc. (ZBIO) stock is 0 as of August 01, 2025.
Does Zenas BioPharma, Inc. stock pay dividends?
No, Zenas BioPharma, Inc. (ZBIO) stock does not pay dividends to its shareholders as of August 01, 2025.
When is the next Zenas BioPharma, Inc. dividend payment date?
Zenas BioPharma, Inc. (ZBIO) stock does not pay dividends to its shareholders.
What is the beta indicator for Zenas BioPharma, Inc.?
Zenas BioPharma, Inc. (ZBIO) does not currently have a Beta indicator.